Despite advances in the therapy of Central Nervous System (CNS) malignancies, treatment
of glioblastoma (GB) poses significant challenges due to GB resistance and high recurrence …

The incidence of glioblastoma (GBM) in the elderly population is slowly increasing in
Western countries. Current management includes surgery, radiation therapy (RT) and …

Background Glioblastoma (GBM) is the most common and lethal primary malignant glioma
in adults. Dendritic cell (DC) vaccines have demonstrated promising results in GBM clinical …

Background 5-Aminolevulic acid-guided surgery (5-ALA-GS) improves the extent of
resection (EoR) and progression-free survival in patients with glioblastoma multiforme …

Background There is an unmet need for new biomarkers able to predict both the outcomes
of up–front therapy and the compliance of elderly patients diagnosed with glioblastoma. For …

Glioblastomas (GBM s) are the most common of both benign and malignant primary brain
tumours, in which the inflammatory and immunologic abnormalities are involved. Interleukin …

Although current treatment advances prolong patient survival, treatment for glioblastoma
(GBM) in the elderly has become an emerging issue. The definition of “elderly” differs across …

Background Glioblastoma multiforme (GBM) has a poor prognosis despite a multi modal
treatment that includes normofractionated radiotherapy. So, various hypofractionated …

Malignant glioma is the most common type of brain tumor with poor clinical outcome and
survival. Therefore, it is imperative to develop novel therapeutic agents for managing glioma …

Background and objective Promoter status of O6-methylguanine-DNA methyltransferase
(MGMT) has been widely established as a clinically relevant factor in glioblastoma (GBM) …